The caveat here is that if one is opting for rhythm control to avoid the need for warfarin in this elderly population, that is not a valid assumption. How should one manage atrial fibrillation ...

The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Ali, MD, MSCIAtrial fibrillation can affect life expectancy due to factors that include age, underlying health conditions, race, and how this common cardiac arrhythmia—or abnormal heart rhythm— is ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

The following is a summary of “Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) ...

a “rate control” strategy and a “rhythm control” strategy. In 2002, the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) randomized trial evaluated the outcomes of ...

Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation ... which patients are best suited for a rhythm-control compared with a rate-control strategy, and what is ...

Hypertension, atrial fibrillation, and smoking are strongly associated with an increased risk for severe vs nonsevere stroke.

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the ...